Patients with hepatitis C virusassociated cirrhosis and clinical significant portal hypertension (CSPH, hepatic venous pressure gradient [HVPG] 10 mmHg or greater), despite achieving sustained virological response (SVR) to therapy, remain at risk of liver decompensation. We investigated hemodynamic changes following SVR in patients with CSPH and whether liver stiffness measurements (LSMs) can rule out the presence of CSPH. METHODS: We performed a multicenter prospective study of 226 patients with hepatitis C virus-associated cirrhosis and CSPH who had SVR to interferonfree therapy at 6 Liver Units in Spain. The portal pressure gradient was determined based on HVPG at baseline and 24 weeks after therapy; patients also underwent right-heart catheterization and LSM at these time points. Primary outcomes were effects of SVR on the hepatic, pulmonary, and systemic hemodynamics; factors related to HVPG 10% reduction and to CSPH persistence; and whether LSMs can rule out the presence of CSPH after SVR. RESULTS: Most patients (75%) had esophageal varices, 21% were Child-B, and 29% had at least 1 previous episode of liver decompensation. Overall, HVPG decreased from 15 (IQR: 12-18) before treatment to 13 (10-16) mmHg after SVR (reduction of 2.1 ± 3.2 mmHg; P < .01). However, CSPH persisted in 78% of patients. HVPG decreased by 10% or more from baseline in 140 patients (62%). Baseline level of albumin below 3.5 g/dL was the only negative factor associated with an HVPG reduction of 10% or more. LSM decreased from 27 (20-37) kPa before treatment to 18 (14-28) kPa after SVR (P < .05). One third of patients with a reduction in LSM to below 13.6 kPa after SVR still had CSPH. A higher baseline HVPG and a lower decrease in LSM after treatment were associated with persistence of CSPH after SVR. Systemic hemodynamics improved after SVR. Interestingly, pulmonary hypertension was present in 13 patients at baseline and 25 after SVR, although only 3 patients had increased pulmonary resistance. CONCLUSIONS: In a multicenter prospective study of patients with hepatitis C virus-associated cirrhosis, an SVR to all-oral therapy significantly reduced HVPG, compared with before treatment. Nevertheless, CSPH persists in most patients despite SVR, indicating persistent risk of decompensation. In this population, changes in LSM do not correlate with HVPG and cut-off values are not reliable in ruling out CSPH after SVR.
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BACKGROUND & AIMS:
Patients with hepatitis C virusassociated cirrhosis and clinical significant portal hypertension (CSPH, hepatic venous pressure gradient [HVPG] 10 mmHg or greater), despite achieving sustained virological response (SVR) to therapy, remain at risk of liver decompensation. We investigated hemodynamic changes following SVR in patients with CSPH and whether liver stiffness measurements (LSMs) can rule out the presence of CSPH. METHODS: We performed a multicenter prospective study of 226 patients with hepatitis C virus-associated cirrhosis and CSPH who had SVR to interferonfree therapy at 6 Liver Units in Spain. The portal pressure gradient was determined based on HVPG at baseline and 24 weeks after therapy; patients also underwent right-heart catheterization and LSM at these time points. Primary outcomes were effects of SVR on the hepatic, pulmonary, and systemic hemodynamics; factors related to HVPG 10% reduction and to CSPH persistence; and whether LSMs can rule out the presence of CSPH after SVR. RESULTS: Most patients (75%) had esophageal varices, 21% were Child-B, and 29% had at least 1 previous episode of liver decompensation. Overall, HVPG decreased from 15 (IQR: 12-18) before treatment to 13 (10-16) mmHg after SVR (reduction of 2.1 ± 3.2 mmHg; P < .01). However, CSPH persisted in 78% of patients. HVPG decreased by 10% or more from baseline in 140 patients (62%). Baseline level of albumin below 3.5 g/dL was the only negative factor associated with an HVPG reduction of 10% or more. LSM decreased from 27 (20-37) kPa before treatment to 18 (14-28) kPa after SVR (P < .05). One third of patients with a reduction in LSM to below 13.6 kPa after SVR still had CSPH. A higher baseline HVPG and a lower decrease in LSM after treatment were associated with persistence of CSPH after SVR. Systemic hemodynamics improved after SVR. Interestingly, pulmonary hypertension was present in 13 patients at baseline and 25 after SVR, although only 3 patients had increased pulmonary resistance. CONCLUSIONS: In a multicenter prospective study of patients with hepatitis C virus-associated cirrhosis, an SVR to all-oral therapy significantly reduced HVPG, compared with before treatment. Nevertheless, CSPH persists in most patients despite SVR, indicating persistent risk of decompensation. In this population, changes in LSM do not correlate with HVPG and cut-off values are not reliable in ruling out CSPH after SVR.
Keywords: Antiviral Therapy; Direct-acting Antivirals; Liver Disease; Portal Hypertension. I n patients with compensated cirrhosis, measurement of the hepatic venous pressure gradient (HVPG) accurately predicts the risk of developing portal hypertension-related complications. 1 Indeed, an HVPG of 10 mmHg or greater (defined as clinically significant portal hypertension [CSPH] ) in patients with compensated cirrhosis is associated with a higher risk of clinical decompensation, development of hepatocellular carcinoma (HCC), and death during follow-up. 1, 2 Additionally, it has been established that in compensated cirrhosis, an HVPG reduction of 10% or more after therapy is associated with a decreased risk of first variceal hemorrhage. 3 In patients with chronic hepatitis C, the main goal of viral clearance is to prevent disease progression. This is especially relevant with the arrival of all-oral antiviral regimens with a better safety profile and sustained virological response (SVR) rates over 90% in patients with cirrhosis. [4] [5] [6] [7] In this setting, the number of patients with hepatitis C virus (HCV) advanced cirrhosis and severe portal hypertension receiving antiviral treatment has dramatically increased, but data regarding the impact of achieving SVR on HVPG is still scarce, especially among those patients with CSPH.
The clinical use of HVPG measurement is limited by its invasiveness, thus the use of noninvasive methods (essentially, transient elastography), to predict the presence of CSPH has gained great interest in recent years because of the relevant implications in patient management. However, most studies were performed in patients with chronic HCV infection and the usefulness of some well-established cutoffs (21 kPa to rule-in and 13.6 kPa to rule-out CSPH) 8, 9 has rarely been evaluated after the achievement of SVR.
In addition, patients with cirrhosis and CSPH usually present a hyperdynamic circulation, characterized by an increase in cardiac output and a decrease in systemic vascular resistance 10 and a fraction of these patients may develop pulmonary arterial hypertension, known as portopulmonary hypertension.
11 Few case reports have described the development of severe pulmonary hypertension (PH) with the use of interferon-free regimens. 12 However, comprehensive data on the impact of SVR after interferonfree regimens on the systemic and pulmonary hemodynamics are not available.
Our study aimed at assessing, in a large cohort of patients with HCV-related cirrhosis and CSPH: (a) the impact of achieving SVR on the hepatic, pulmonary and systemic hemodynamics; (b) identify the predictors of HVPG response (decrease 10%) and of persistence of CSPH; and (c) the clinical value of transient elastography to rule out the presence of CSPH after SVR.
Patients and Methods

Patients and Study Design
This is a multicenter prospective study of patients with HCV-related cirrhosis undergoing interferon-free antiviral therapy in 6 Liver Units in Spain [Hospital Clínic (Barcelona), Hospital Sant Pau (Barcelona), Hospital Puerta del Hierro (Madrid), Hospital Ramón y Cajal (Madrid), Hospital Gregorio Marañón (Madrid), and Hospital Marqués de Valdecilla (Santander)]. Inclusion criteria for the study were the presence of CSPH at baseline (within 6 months before all-oral antiviral treatment) and the achievement of SVR. A cut-off of 13.6 Kpa was used as screening to propose patient participation in the study. 8, 9 Those patients starting nonselective beta blocker (NSBB) therapy within the study period or those with other causes of liver disease, such as coinfection with hepatitis B virus or human immunodeficiency virus or active alcoholic liver disease were excluded. Patients underwent HVPG, right-heart catheterization, and liver stiffness measurement (LSM) at baseline and 24 weeks after the end of treatment. The local ethics committee approved the study protocol and all patients signed informed written consent.
Antiviral Treatment
The decision to treat was at the discretion of the treating physician, following the current recommendations of EASL Guidelines and Spanish Association for the Study of the Liver. 13, 14 All-oral antiviral regimens included the combination of different direct-acting antivirals (DAAs): sofosbuvir (SOF) with simeprevir, ledipasvir, daclatasvir, or ribavirin (RBV), as well as the combination of ritonavir-boosted paritaprevir with ombitasvir and dasabuvir. The therapeutic regimen, duration, or addition of RBV was indicated according to current clinical recommendations. 13 Weight-based dose RBV was used when indicated; dose modification or supportive treatment with erythropoietin was based on internal protocols. Viral load measurements were reported at baseline and at 12 and 24 weeks after treatment completion. SVR was defined as an undetectable HCV-RNA 12 and 24 weeks after the end of treatment. Virological failure was considered if HCV-RNA became detectable during treatment or post-treatment followup. HCV-RNA levels were determined using either the COBAS AmpliPrep/COBAS TaqMan (Roche Molecular Systems, Pleasanton, CA; lower limit of detection, 15 IU/mL) or the m2000SP/ m2000RT (Abbott Molecular, Des Moines, IL; lower limit of detection, 12 IU/mL) real-time polymerase chain reactionbased assays, according to the available method in the different centers.
HVPG and LSM
Hemodynamic studies were performed after overnight fasting under light sedation with intravenous midazolam. Under local anesthesia, a venous introducer was placed in the right internal jugular vein using the Seldinger technique. Under fluoroscopy, a 7F balloon-tipped catheter (Edwards
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Lifesciences, Irvine, CA) was guided into the main right hepatic vein for measurements of wedged hepatic venous pressure and free hepatic venous pressure. The adequate occlusion of the hepatic vein was checked by manual injection of a small amount of radiologic contrast medium. Free hepatic venous pressure was measured in the right hepatic vein close to the inferior vena cava. The portal pressure gradient was measured as HVPG (the difference between wedged hepatic venous pressure and free hepatic venous pressure).
Patients were classified in terms of the severity of CSPH according to previous clinically relevant described HVPG cutoffs: HVPG 12 mmHg associated with a higher risk of bleeding and ascites, and HVPG 16 mmHg associated with a higher risk of mortality.
3,15 NSBB therapy was indicated according to current clinical recommendations. A clinically relevant HVPG response was defined as a decrease 10% from baseline. 3 The following parameters were recorded during right-heart catheterization: heart rate, arterial pressure, central venous pressure, cardiac output, systemic vascular resistance, mean pulmonary arterial pressure, pulmonary capillary wedged pressure, and pulmonary vascular resistance (PuVR). Pulmonary arterial hypertension was defined by a mean pulmonary arterial pressure (mPAP) 25 mmHg. Portopulmonary hypertension was defined as pulmonary arterial hypertension with pulmonary capillary wedged pressure 15 mmHg and PuVR >240 dyn s/cm 5 .
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Measurement of liver stiffness was performed by transient elastography (Fibroscan; Echosens, Paris, France), as previously described 17 at baseline and 24 weeks after antiviral treatment.
Statistical Analysis
Continuous variables are reported as median (interquartile range [IQR] ) and categorical variables are reported as absolute and relative frequencies. Groups were compared using the t test or the Mann-Whitney test for continuous variables when appropriate, and the Fisher exact test was used for categorical variables. For those paired variables (baseline and follow-up), Wilcoxon or paired t test analysis were used when appropriate. Logistic regression models were used to study the predictors of HVPG response or persistence of CSPH. Variables with 0.10 significance on univariate tests were included in the multivariate analysis by forward stepwise conditional. Significance was established as a 2-sided P value of .05. The analysis was performed with IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp, Armonk, NY).
Results
Baseline Characteristics
Between July 2014 and April 2016, 934 patients with HCV-related cirrhosis were treated with all-oral antiviral therapy in the 6 centers involved in the study. Overall, 57% of patients with cirrhosis (n ¼ 532) underwent an HVPG measurement. The remaining patients had either a baseline LSM <13.6 kPa, refused to participate in the study, or were excluded for other reasons. Of those patients undergoing HVPG assessment, 52% had an HVPG 10 mmHg and were included in the study (n ¼ 277). Of 277 patients with baseline CSPH, 226 patients with SVR and paired HVPG assessment were included in the final analysis ( Figure 1 ). As shown in Supplementary Table 1, there were no significant differences in HVPG values at baseline or severity of liver disease between patients with CSPH included or not in the study. Table 1 depicts baseline characteristics of the study cohort. Overall, 53% were male with a mean age of 60 years (range, 40-83). Regarding liver disease, 66 patients (29%) presented decompensation and 47 patients (21%) were Child-Pugh Turcotte (CPT) stage B (CPT-B). Of those with available data (n ¼ 210), 75% had esophageal varices (large in 43%). In addition, 103 patients (47%) were under treatment with stable dose of NSBB therapy. Seventy percent of patients were genotype 1b and almost half of the cohort had failed a previous antiviral treatment. The most used combinations were ledipasvir/SOF (36%) followed by ritonavir-boosted paritaprevir with ombitasvir and dasabuvir, and SOF/simeprevir (26% each). Seventysix percent of patients underwent a 12-week course of antiviral therapy and 80% received concomitant therapy with RBV.
Baseline HVPG and Impact of SVR SVR to all-oral antiviral therapy resulted in a significant decrease of HVPG values 24 weeks after end of treatment (follow-up HVPG) with mean HVPG values of 13.4 ± 4.7 mmHg (range, 4-29) with an absolute delta change of -2.1 ± 3.2 mmHg and a relative delta of -13 ± 20% from baseline (P < .05) (Figure 2A ). According to HVPG strata, absolute and relative delta change was -2.1 ± 3.3 mmHg and -12 ± 18% for those patients with baseline-HVPG 12 mmHg; and -2.6 ± 3.9 mmHg and -14 ± 20% for those with baseline-HVPG 16 mmHg. Patients with large varices presented a lower relative HVPG decrease after treatment compared with those with small or no varices, although the difference did not reach statistical significance (-8% vs -14% vs -17%, respectively; P ¼ .18). Relative HVPG decrease after therapy was statistically lower among patients with decompensated cirrhosis (-8 ± 19% vs -16 ± 19%, P < .01).
Despite HVPG reduction after SVR, CSPH persisted in 176 (78%) patients; 142 (63%) still had an HVPG 12 mmHg and 57 (25%) an HVPG 16 mmHg ( Figure 2B ). Although HVPG decreased or did not change in most patients (77% and 13%, respectively), 39 patients (17%) presented an increase in HVPG values despite achieving SVR.
Predictors of HVPG Response
After achieving SVR, 140 patients (62%) presented an HVPG reduction of 10% from baseline (10% HVPG responders) and 90 patients (39.8%) of 20%. As shown in Table 2 , 10% HVPG responders had higher albumin levels and lower LSM values than HVPG non-responders; however, baseline-HVPG values were not significantly different between both groups of patients. At multivariate analysis including albumin, LSM, and decompensation, only the presence of lower baseline albumin levels remained as an independent negative predictor of 10% HVPG response after therapy (overall response [OR] [95% CI] 0.52 [0.27-0.59]; P ¼ .04) ( Table 2) .
When defining response as either an HVPG reduction of 20% from baseline or an HVPG value <12 mmHg after SVR, baseline HVPG and LSM were significantly lower in responders (116, 51.3%) than in non-responders with OR (95% CI) of 0.92 (0.85-0.98); P ¼ .02 and 0.97 (0.95-0.99); P ¼ .01, respectively (Supplementary Table 2 ).
Predictors of CSPH (HVPG 10 mmHg) After SVR
As shown in Table 3 , the presence of esophageal varices, history of ascites, lower albumin and platelet count, higher Model for End-Stage Liver Disease (MELD), worse ChildPugh class, and higher HVPG and LSM at baseline were associated with a higher probability of remaining with CSPH 24 weeks after the end of therapy with DAA. In addition, these patients had a significantly lower relative reduction in LSM after antiviral treatment.
At multivariate analysis, including low albumin and platelet levels, decompensation, esophageal varices, and baseline-HVPG (Model I), a higher HVPG (OR 1.9 [1.5-2.5]; P < .01) and the presence of esophageal varices (OR 3.2 [1.2-8.3]; P ¼ .02) were independent predictors of CSPH persistence despite achievement of SVR. When the model included baseline LSM and change in LSM (Model II, n ¼ 171 patients), the independent factors associated to CSPH persistence were baseline HVPG (OR 1.7 [1.5-3.0]; P < .01) and a lower delta decline in LSM after SVR (OR 1.03 [1.01-1.05]; P ¼ .02) ( Table 3) .
HVPG Increase Despite SVR
Thirty-nine patients (17%) presented an increase in HVPG values despite achieving SVR (mean increase, þ2.8 ± 1.7 mmHg, 18 ± 11%). No significant differences were observed in baseline HVPG or LSM values between patients with HVPG increase or not. However, patients with an increase in HVPG after SVR had a significantly higher prevalence of esophageal varices and previous variceal bleeding and lower platelet count. In addition, these patients had a lower reduction in LSM values after antiviral treatment. In multivariate analysis, including child score, variceal bleeding, baseline platelets, and decompensation, only previous acute variceal bleeding and the presence of thrombocytopenia were independently associated to HVPG increase after SVR (Supplementary Table 3 ). Other causes that may be associated with an HVPG increase such as weight gain or concomitant alcohol consumption during the study period were discarded.
LSM as a Predictor of CSPH After SVR
Paired LSM assessment was available in 171 patients (75% of the cohort). There were no significant baseline differences between the overall cohort and the group of patients with paired LSM assessment (data not shown).
Baseline LSM was 27 (20-39) kPa and decreased significantly to 18 (14-29) kPa after SVR (delta change -6.8 ± 11 kPa, and relative delta -19 ± 30%; P < .05). Although statistically significant (P ¼ .04), the correlation between changes in HVPG and LSM were very poor (r ¼ 0.16) (Supplementary Figure 1) . The areas under the receiver operating characteristic curves (AUROCs) for the diagnosis of follow-up CSPH were moderately good (0.71 and 0.80) for baseline LSM and for follow-up LSM, respectively (Supplementary Figure 2) .
The predictive value of previously described LSM cutoffs to rule in (21 kPa) or out (13.6 kPa) the presence of CSPH after SVR was evaluated. 8, 9 As shown in Table 4 , CSPH persisted in 71 (91%) of 78 patients with follow-up LSM 21 kPa and 45 (80%) of 56 patients with follow-up LSM 13.6-21 kPa. Thus, the cut-off 21 kPa still had a high positive predictive value (91%) to rule in the presence of CSPH after SVR (Table 4) . However, it is important to notice that the cut-off <13.6 performed poorly to rule out CSPH after SVR, indeed among the 37 patients with follow-up LSM <13.6 kPa, 16 patients (43%) still had CSPH.
When specifically analyzing the 157 patients with baseline LSM 13.6 kPa, 24 (15%) of them exhibited a reduction below this threshold. However, despite LSM decrease to a "safe area" of <13.6 kPa, 8, 9 one third of patients (9 of 24, 37%) still presented CSPH, further confirming that the presence of CSPH cannot be completely ruled out by a low liver stiffness value after therapy (Supplementary Figure 3) . To avoid an influence of previous decompensation on LSM assessment, we analyzed the performance of LSM only in compensated patients (n¼160). The AUROCs for the diagnosis of follow-up CSPH did not improve as compared with the overall cohort (0.67 and 0.75 for baseline LSM and for follow-up LSM, respectively) and 42% of compensated patients with follow-up LSM <13.6 kPa still presented CSPH.
Clinical Evolution During Follow-up
Five patients (5/160, 3%) developed de novo decompensation (4 ascites and 1 hepatic encephalopathy) a mean of 22 weeks after treatment initiation (range, 4-47) (Supplementary Table 4 ). In addition, 6 patients with previous liver decompensation (5 of 66, 7.6%) presented a new episode or worsening of current decompensation a mean of 14 weeks after treatment initiation (range, 5-30). Five patients with ascites developed hepatic encephalopathy (n ¼ 2), variceal bleeding (n ¼ 2), or worsening of ascites (n ¼ 1), and 1 patient with previous variceal hemorrhage had a new bleeding episode. Importantly, all patients had persistent CSPH at follow-up. HCC was diagnosed in 2 patients (2 of 219, 0.9%) 1 and 8 weeks after treatment initiation and in 1 patient with previous HCC in complete remission (1 of 7, 14%) 24 weeks after initiation of antiviral therapy; all of them with CSPH after SVR. No patient died or was transplanted during the study period.
Systemic and Pulmonary Hemodynamics
Paired systemic and pulmonary hemodynamic data were available for 157 patients. There were no differences in baseline variables between patients with and without available systemic and pulmonary hemodynamics (data not shown). Baseline HVPG values and HVPG change after SVR were similar to that observed in the whole cohort: 15 (12.2-18.5) to 13 (10-16) mmHg; delta -2.3 ± 3 mmHg; P < .01). As shown in Figure 3 , SVR induced a mild but statistically significant increase in MAP and in systemic vascular resistance. In addition, there was a significant decrease in cardiac output.
Interestingly, mPAP and PuVR also rose after treatment, although the increase was mild. At baseline, 13 patients presented with PH defined by mPAP 25 mmHg, with mPAP ranging between 25 and 37 mmHg. After therapy, PH persisted in 8 of these patients (61%) and developed in 17 additional patients, with a total of 25 patients with PH on follow-up (range, 25-39 mmHg). This represents a 20 (23) 27 (19) .50 MELD score 9 (7-11) 9 (7-11 significant increase in the prevalence of PH after SVR (P < .01). Nevertheless, it is important to remark that only 2 patients at baseline and 3 patients on follow-up presented increased PuVR (PuVR >240 dyn/m 2 ) and accomplished portopulmonary hypertension criteria (Supplementary Table 5 ).
Discussion
Development of CSPH is a hallmark in the natural history of cirrhosis because it is associated with a higher risk of hepatic decompensation and increased risk of HCC and death. 1, 2, 18 The clinical benefits of SVR in patients with HCVassociated cirrhosis have been widely demonstrated. 19 However, clinicians must keep in mind that previous data from the interferon era have proven that despite viral eradication, patients with persistent CSPH after SVR remain at risk for liver-related complications. 20 Importantly, the profile of patients treated in the interferon era was significantly different because the presence of direct or indirect signs of portal hypertension were contraindications for the use of interferon. Moreover, interferon-based treatments were longer (48 weeks), viral decline was slower, and interferon had some specific properties such as immunemodulator or anti-proliferative that may account for some differences in terms of hemodynamic improvement after therapy. Thus, information on the impact of HCV eradication in this population is scarce and may not be indicative of what happens in patients with more advanced liver disease receiving all-oral antiviral therapy.
Our study was performed in large cohort of patients with cirrhosis and CSPH, most of them with esophageal varices and/or previous clinical decompensation. The results clearly show that HVPG is significantly reduced when evaluated 24 weeks after obtaining SVR with the use of interferon-free regimens. A 13% mean reduction of HVPG is considerable, close to that obtained with traditional NSBB and to that observed in patients achieving SVR after a 1-year treatment with interferon-based regimens. 21, 22 A similar reduction in HVPG was reported in a recent study by Mandorfer and collaborators. 23 However, patients included in this smaller and retrospective study presented less severe liver disease (only 41 of 60 patients [68%] had CSPH at baseline and only 9 were CPT-B [15%]) and the time interval between the end of treatment and follow-up HVPG measurement was not standardized, hindering the evaluation of the true impact of SVR on HVPG. In a clinical trial assessing the effect on portal pressure of a 48-week treatment with SOF/RBV in a cohort of cirrhotics (n ¼ 37), 24 the observed HVPG decrease at the end of treatment was less marked (mean 1.2 ± 4.5 mmHg). Nevertheless, baseline HVPG was slightly higher (16.5 mmHg) and there were a high proportion of patients with decompensation (57%) and CPT-B score (62%).
Similar to Mandorfer's study, 23 we observed a negative association between the degree of liver impairment and the chance of an HVPG response 10%. However, albumin levels 3.5 g/dL (and not CPT-B score) was the only negative independent predictor for HVPG response in our study. Importantly, the degree of portal hypertension at baseline was not different between those patients achieving an HVPG response or not in either study. On the other hand, when defining HVPG response as an HVPG decrease 20% from baseline or below <12 mmHg after treatment, higher baseline HVPG and LSM values were the only negative predictors of HVPG response. LRþ, positive likelihood ratio; LR-, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, specificity. It is relevant to highlight that in spite of a significant HVPG reduction at 6 months after the end of therapy, CSPH persisted in a high proportion of patients (78%), implying that these patients remain at high risk of developing complications of portal hypertension and HCC. Indeed, 3% of patients presented de novo decompensation and a proportion of previously decompensated patients (7.6%) developed a new decompensation episode. A greater baseline HVPG and the presence of esophageal varices, as well as a less marked reduction in LSM after treatment, were independent factors associated with persistence of CSPH despite successful antiviral therapy. Nonetheless, the correlation between LSM change and HVPG reduction was very weak in our study, even if statistically significant. Although follow-up LSM had a moderately good AUROC (0.80) for the identification of CSPH after treatment, the potential value of previously described LSM cut-offs 8, 9 to identify patients with or without CSPH after viral clearance was far from ideal. After SVR, almost half of those patients with an LSM value below 13.6 kPa (the threshold that has shown a high predictive value to rule out the presence of CSPH in patients with active HCV infection) still present CSPH. By contrast, most patients with a LSM 21 kPa or between 13.6-21.0 kPa had CSPH. These results were similar if only considering patients with compensated cirrhosis. Thus, the diagnostic accuracy of LSM to rule out CSPH 24 weeks after obtaining SVR appears poor and the evidence of CSPH regression, at least in this clinical setting, remains HVPGdriven and cannot completely be substituted by noninvasive tools.
An interesting finding was the identification of a subgroup of patients (37%) presenting an HVPG increase despite successful antiviral therapy. The proportion of patients showing an increase in HVPG at follow-up was similar to previous studies (approximately 20%). 23 After exclusion of other causes of fibrosis progression, it cannot be discarded that among those patients with advanced liver disease there may be a point of no return in the evolution of cirrhosis, despite successful removal of the etiologic agent. Indeed, in our study those patients presenting an increase in HVPG at follow-up had more frequent previous episodes of decompensation, esophageal varices, and low albumin and platelet levels.
We cannot exclude, however, an overall further HVPG time-dependent reduction because regression of fibrosis in patients with advanced cirrhosis (and portal hypertension) may be delayed during an undetermined period of time after the etiologic treatment of the underlying liver disease. Indeed, in a previous study from our group, 20 HVPG measurements performed in a small subset of patients a median of 5 years (IQR, 3-6) after achieving SVR (with interferonbased antiviral treatment) showed further decreases of HVPG. A similar observation was made in a recent study on SOF/RBV-treated patients where 8 of 9 patients had a further 20% reduction in HVPG at 48 weeks of followup. 24 Therefore, further HVPG evaluations after a longer follow-up period are warranted.
Unfortunately, paired liver biopsies to study in detail the mechanism for the HVPG reduction after SVR are not available. However, we can speculate that because of the short period of follow-up, HVPG reduction could be more related to changes in necroinflammation than fibrosis itself (requiring more time to improve significantly). Portal blood flow was not measured; however, the observed increase in systemic vascular resistance may support a potential increase in splanchnic vascular resistance with a possible reduction in portal blood flow that could contribute to the reduction in HVPG.
Indeed, in advanced stages (coincident with occurrence of CSPH), portal hypertension is aggravated by splanchnic and systemic vasodilatation with reduced systemic vascular resistance and increased cardiac output characterizing a hyperdynamic circulation. 10, 25 This is the first study demonstrating an improvement of systemic hemodynamic parameters after SVR in a cohort of patients with advanced liver disease and CSPH. On the other hand, few reports have previously associated interferon treatment as a risk factor for the development of pulmonary arterial hypertension. 26 In addition, a potential link between the use of DAAs and exacerbation or development of pulmonary arterial hypertension has recently been suggested. 12, 27 One hypothesis would be that a decrease in vasodilator inflammatory mediators (because of a rapid suppression of HCV replication by DAA) may be responsible of this phenomenon. 12, 27 However, the information on this topic is limited and more data are needed to draw solid conclusions. Interestingly, in our cohort of patients with CSPH, mPAP, pulmonary capillary wedged pressure, and PuVR increased after DAA therapy (independently of the type of antiviral regimen). Although the increase was mild, the number of patients with an mPAP 25 mmHg increased from 13 before treatment to 25 after treatment. However, only 3 of these patients presented a PuVR slightly over the threshold, characterizing the diagnosis of portopulmonary hypertension (240 dyn s/cm 5 ) and, none of the patients presented functional or clinical symptoms.
The main limitations of our study arise from the short follow-up period; the performance of HVPG and LSM only 24 weeks after end of therapy may hinder the true impact of suppressing HCV infection. Secondly, not all cirrhotic patients receiving all-oral antiviral therapy in the centers underwent a hemodynamic assessment and not all patients with CSPH and achieving SVR to all-oral antiviral therapy underwent follow-up HVPG measurement because of different causes; so a selection bias cannot be completely excluded. Furthermore, it is relevant to point out that no patient with Child-Pugh Turcotte C cirrhosis was included in the study, thus the findings of our study may not be translated to these patients with marked liver impairment. However, and despite these limitations, we believe that the large size of the cohort allows for extracting solid conclusions in patients with CSPH.
In conclusion, SVR to all-oral antiviral regimens is associated with a reduction in portal pressure in patients with CSPH at baseline. Despite this reduction, CSPH persists in the majority of patients (approximately 80%), which is potentially linked to a persistent risk of liver-related events during an undetermined period of time. A reduction of LSM to values <13.6 kPa after SVR does not have a good discriminative capacity to rule out the presence of CSPH in these patients; thus, it is relevant to closely monitor patients with CSPH despite a relevant LSM reduction after SVR. Finally, although systemic hemodynamics improved after SVR, the real impact of these regimens in patients with portal hypertension and elevated pulmonary arterial pressure should be further studied.
